This is a shortened version of an article written by Kristi Rosa and published in OncLive March 24, 2022
Wednesday, March 30, 2022
Friday, March 18, 2022
Let's Support Our Sister Organization:
Ashton Thompson becomes the first National Ovarian Cancer Coalition (NOCC) Athletic Ambassador, committed to spreading awareness on and off the track
As an Athletic Ambassador for the organization, Thompson will support early awareness and education initiatives in a sport with plenty of female fans, but few female drivers to look up to. As the only female driver in the field this race season, Thompson’s unique perspective and passion for racing will inspire women across the country to take action and advocate for their health. "We are proud to have Ashton join us in bringing much-needed awareness to ovarian cancer,” shared NOCC CEO Melissa Aucoin, “ a disease that impacts over 21,000 women in the U.S each year, and so grateful to have her heroic commitment in reaching and empowering new audiences of women everywhere with lifesaving health messages."
NOCC and Ashton Thompson Racing are excited to partner during the 2022 race season to break barriers on the track and break the silence on ovarian cancer. To learn more about the 2022 Kenyon Midget Race Season and where you can catch Ashton, visit ashtonthompsonracing.org.
Friday, March 11, 2022
This article is taken from ScienceDaily
Every year, roughly 550 women develop ovarian cancer in Finland. Ovarian cancer is difficult to treat and it is commonly fatal, with 320 women dying of ovarian cancer annually in Finland.
Thursday, March 10, 2022
Veiseh, an assistant professor of bioengineering whose lab produced the treatment, said human clinical trials could begin as soon as this fall because one of his team’s key design criteria was helping cancer patients as quickly as possible. The team chose only components that had previously proven safe for use in humans, and it has demonstrated the safety of the new treatment in multiple tests.
“We just administer once, but the drug factories keep making the dose every day, where it’s needed until the cancer is eliminated,” Veiseh said. “Once we determined the correct dose — how many factories we needed — we were able to eradicate tumors in 100% of animals with ovarian cancer and in seven of eight animals with colorectal cancer.”
Interleukin-2 is a cytokine, a protein the immune system uses to recognize and fight disease. It is an FDA-approved cancer treatment, but Nash, a graduate student in Veiseh’s group and the study’s lead author, said the drug factories provoke a stronger immune response than existing interleukin-2 treatment regimens because the beads deliver higher concentrations of the protein directly to tumors.
“If you gave the same concentration of the protein through an IV pump, it would be extremely toxic,” Nash said. “With the drug factories, the concentration we see elsewhere in the body, away from the tumor site, is actually lower than what patients have to tolerate with IV treatments. The high concentration is only at the tumor site.”Nash said the same general approach used in the study could be applied to treat cancers of the pancreas, liver, lungs and other organs. The drug factories could be placed next to tumors and within the linings that surround those organs and most others, she said. And if a different cytokine is needed to target a specific form of cancer, the beads can be loaded with engineered cells that make that immunotherapeutic compound.
The bead’s outer shell shields its cytokine-producing cells from immune attacks. The shells are made of materials the immune system recognizes as foreign objects but not as immediate threats, and Veiseh’s lab leveraged that in its design.
“We found foreign body reactions safely and robustly turned off the flow of cytokine from the capsules within 30 days,” he said. “We also showed we could safely administer a second course of treatment should it become necessary in the clinic.”
Avenge Bio , a Massachusetts-based startup co-founded by Veiseh, has licensed the cytokine-factory technology from Rice.
Additional co-authors include Maria Jarvis, Samira Aghlara-Fotovat, Sudip Mukherjee, Andrea Hernandez, Andrew Hecht, Yufei Cui, Shirin Nouraein, Jared Lee, David Zhang and Oleg Igoshin of Rice; Peter Rios, Sofia Ghani, Ira Joshi and Douglas Isa of CellTrans Inc.; Chunyu Xu and Weiyi Peng of the University of Houston; Rahul Sheth of MD Anderson; and José Oberholzer of both CellTrans Inc. and the University of Virginia.
The research was funded by the Cancer Prevention Research Institute of Texas (RR160047), Avenge Bio, the Emerson Collective, the Welch Foundation, the Rice University Academy of Fellows, the National Science Foundation (1842494) and the National Institutes of Health (R01DK120459).
Jazaeri receives compensation as a consultant on Avenge Bio’s scientific advisory board and has disclosed the relationship to MD Anderson in accordance with its conflict-of-interest policy. Nash, Jarvis, Aghlara-Fotovat, Mukherjee, Hecht, Igoshin, Zhang and Veiseh declared interests via patents filed by Rice on the cytokine factories. Igoshin, Veiseh and Oberholzer are paid consultants for Avenge Bio. Nash, Zhang, Sheth, Oberholzer, Jazaeri and Veiseh hold equity in Avenge Bio.
Wednesday, March 9, 2022
This article is taken from ScienceDaily.
Tuesday, March 8, 2022
OncLive presents "Latest Perspective in Ovarian Cancer Care". Below are the topics that will be covered. Here is the link to watch this on-demand video.
The closer we look, the further we’ll go
Highlighting the current state of ovarian cancer and current treatments to understand the challenges faced by those living with ovarian cancer.
What if the treatments were as unique as the tumor?
Understanding the history of where we’ve been with ovarian cancer, and what’s in store for the future, and your role in it.
To test is to know what to target
Exploring the advances in genomic profiling of ovarian cancer tumors and optimizing treatment outcomes for patients.
Using the journey to define the destination
Applying personalized treatments in practice and the impacts these can have on those living with ovarian cancer.
Monday, March 7, 2022
The results, published in Science Advances on Wednesday, suggest that it may eventually be possible to better detect and manage those at risk of progression after chemotherapy treatment.
“Our findings help to identify already, prior to treatment, the tumors that are the most likely to have a poor response to therapy,” co-senior and co-corresponding author Anna Vähärautio, a researcher at the University of Helsinki, said in a statement. “Our results also suggest that therapies could be targeted at the inflammatory microenvironment of cancer cells and the surrounding tissue to improve treatment outcomes with the help of combination therapy.”
Vähärautio and her colleagues searched for transcriptome features corresponding with resistance to neoadjuvant chemotherapy using single-cell RNA sequence profiles for nearly 51,800 tumor, stromal, or immune cells from high-grade serous ovarian cancer samples collected prospectively from 11 patients at Turku University Hospital. They also considered RNA in situ hybridization data for 10 of the matched pre- and post-treatment tumor sets, along with bulk RNA-seq data for dozens more paired pre- and post-treatment or pre-treatment and relapse samples.
The team analyzed RNA-seq profiles in pre-treatment diagnostic laparoscopy samples and in post-chemotherapy samples obtained after debulking surgery using a computational method called PRIMUS that was designed to dial down patient-specific features to find shared transcriptional signals linked to chemotherapy response.
In ovarian cancer patients with chemotherapy-resistant tumors primed to progress to metastasis, they found a rise in stress-associated cell features that had been present in baseline samples.
“The stress-associated state exists before chemotherapy, is subclonally enriched during the treatment, and associates with poor progression-free survival,” the authors reported. “Co-occurrence with an inflammatory cancer-associated fibroblast subtype in tumors implies that chemotherapy is associated with stress response in both cancer cells and stroma, driving a paracrine feed-forward loop.”
Those results lined up with patterns found in another 271 individuals with ovarian cancer who had their pre-treatment tumors tested by bulk RNA-seq through the Cancer Genome Atlas project, the researchers reported. Along with available gene expression profiles, they used reverse-phase protein array testing to distinguish between cases with stress-high or stress-low tumors.
That group included 86 individuals with high-grade serous ovarian tumors classified as stress-high and 144 individuals with stress-low tumors, the team noted. While the median progression-free survival time was 21.2 months for patients with stress-low tumors, it dropped to just shy of 15 months in the subset of patients with ovarian tumors showing high levels of stress-associated features.
With expression profiles for more than a dozen immune or stromal cell types that turned up in the tumor microenvironment samples, meanwhile, the researchers found related inflammation and paracrine signaling in stromal cells in the microenvironment of tumors showing stress-associated features, along with enhanced representation of cancer-associated fibroblast cells.
Based on these and other findings, the authors suggested that “a combination of induced and selective processes” contribute to the transcriptomic changes detected following chemotherapy — shifts that may be influenced by everything from tumor microenvironment features to differences in an individual’s underlying genetics and biology.
“[T]he identification of [a] stress signature opens avenues for combinatorial drug testing in preclinical models that maintain both subclonal heterogeneity and paracrine tumor-stromal signaling,” they concluded. “As many drugs targeting inflammatory effectors are already in clinical use for other indications, they may offer a realistic option for safe combinatorial therapies with a wide array of currently used oncological drugs to restrain the broadly adaptive stress response of tumors.”
This article was published by Genome Web.
Thursday, March 3, 2022
Tuesday, March 1, 2022
Clearity Foundation has put together a search option to help you and your doctor select the best clinical trial for you. A link to that is below. If you haven't spent any time on the Clearity Foundation website, I would urge you to do so. It provides free counseling to women with OC and articles about research and links to treatment decision supports and what to do if you're newly diagnosed.
In regards to finding clinical trials, there is a seven minute video tutorial that they have published on finding clinical trials You can find a link to this video here.